Dan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dan Li has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Yongsheng Wang
Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
21 shared publications - Mingyang Feng
West China Hospital of Sichuan University 2 State Key Laboratory of Biotherapy and Cancer Center Chengdu, China
13 shared publications - Benxia Zhang
West China Hospital of Sichuan University 5 Clinical Trial Center Chengdu, China
12 shared publications - Bo Zhu
Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
12 shared publications - Diyuan Qin
West China Hospital of Sichuan University 1 Division of Thoracic Tumor Multimodality Treatment, Cancer Center Chengdu, China
12 shared publications - Fu-Chun Guo
West China Hospital of Sichuan University 5 Clinical Trial Center Chengdu, China
12 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S10 shows antitumor efficacy of DLL3 TriTCE monotherapy and its in vitro synergistic effects with DBBζ.CBB CAR-T cells
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S10 shows antitumor efficacy of DLL3 TriTCE monotherapy and its in vitro synergistic effects with DBBζ.CBB CAR-T cells
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S1 demonstrates that VHH-based second-generation DLL3 CAR-T cells exhibit potent in vitro cytotoxicity.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S1 demonstrates that VHH-based second-generation DLL3 CAR-T cells exhibit potent in vitro cytotoxicity.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S11 shows representative flow cytometric gating strategies.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S11 shows representative flow cytometric gating strategies.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S4 shows the functional comparison of different B7H3/CD56 CAR-T cell designs and demonstrates that incorporation of parallel 4-1BB signaling confers superior functionality.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S4 shows the functional comparison of different B7H3/CD56 CAR-T cell designs and demonstrates that incorporation of parallel 4-1BB signaling confers superior functionality.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S3 shows the cytotoxicity comparison between N-DBBζ.C28 and DBBζ.C28 CAR-T cells, revealing reduced killing activity of N-DBBζ.C28 CAR-T cells.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S3 shows the cytotoxicity comparison between N-DBBζ.C28 and DBBζ.C28 CAR-T cells, revealing reduced killing activity of N-DBBζ.C28 CAR-T cells.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S2 shows the validation of tumor antigen expression and the assessment of CAR expression during in vitro expansion.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S2 shows the validation of tumor antigen expression and the assessment of CAR expression during in vitro expansion.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S5 shows the single-cell RNA sequencing (scRNA-seq) analysis of intratumoral T cells from different CAR-T cell treatment groups, including characterization of T-cell subsets and transcriptional profiles.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S5 shows the single-cell RNA sequencing (scRNA-seq) analysis of intratumoral T cells from different CAR-T cell treatment groups, including characterization of T-cell subsets and transcriptional profiles.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S7 shows the functional advantages of DBBζ.CBB require CBB CSR engagement.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S7 shows the functional advantages of DBBζ.CBB require CBB CSR engagement.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S6 shows the CellChat analysis of different CAR-T cell treatment groups, revealing differences in intercellular communication networks.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S6 shows the CellChat analysis of different CAR-T cell treatment groups, revealing differences in intercellular communication networks.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S8 shows parallel 4-1BB signaling sustains tumor infiltration, drives robust effector differentiation, and delays in vivo exhaustion.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
Figure S8 shows parallel 4-1BB signaling sustains tumor infiltration, drives robust effector differentiation, and delays in vivo exhaustion.